

## **Thyroid and Parathyroid Disease**

Priya Dedhia, MD, PhD
Assistant Professor
Department of Surgery
Division of Surgical Oncology
The Ohio State University Wexner Medical Center

THE OHIO STATE UNIVER

**No Disclosures** 

## Agenda

- Thyroid nodules and cancer
  - Imaging
  - Indications for FNA
  - · Common FNA results
  - Extent of surgery
- PHPT
  - Definition of "Asymptomatic" PHPT
  - Indications for Parathyroidectomy
  - · Benefits of Parathyroidectomy





A patient was found to have a possible thyroid nodule on CT scan...



## Thyroid nodules are common

| En  | docrine Condition | Prevalence |
|-----|-------------------|------------|
| Thy | roid nodules      | 30-70%     |
| Me  | tabolic syndrome  | 35-40%     |
| Ob  | esity             | 25-50%     |
| Ну  | perlipidemia      | 15-20%     |
| Dia | betes             | 5-25%      |
| Os  | teoporosis        | 7%         |

Golden SH., et al. J Clin Endo Metab 2009; 94:1853-78 Mazzaferri M. New England Journal Medicine 1993; 328:553-558 Guth S. et al. Fur. I Clin Invest 2009; 30:590-706

## Thyroid nodules - background


• Up to 15% of nodules are cancer


| Study          | Number of<br>Biopsies | Malignant (%) |
|----------------|-----------------------|---------------|
| Yassa 2007     | 3589                  | 14%           |
| Theoharis 2009 | 3207                  | 15%           |
| Yang 2007      | 4703                  | 7.6%          |



· Which ones to resect?

Yassa L., et al. Cancer Cytopathology 2007; 111(6):508-16 Theoharis, C., et al. Thyroid 2009, 19(11):1215-23 Yang J., et al. Cancer Cytopathology 2007; 111(5):306-15





## **American Thyroid Association Guidelines**

Thyroid sonography should be performed in all patients with known or suspected thyroid nodules.

Strong recommendation, high-quality evidence

Haugen 2016 Thyroid

A patient was found to have a possible thyroid nodule on CT scan...

> Get TSH and an ultrasound!



## **Evaluation of a New Thyroid Nodule - Imaging**

- Ultrasound
  - · Most useful, only test needed for most
- Thyroid Scintigraphy
  - · Reserved for hyperthyroid work-up
- CT
  - · Rarely indicated
  - Substernal extension
  - · Extensive nodal disease
  - · Suspicion of MTC or ATC



## Thyroid ultrasound




- Nodule
  - Size
  - Location Composition

  - Echogenicity Margins
  - Presence of calcifications
  - · Taller than wide
  - Vascularity

- Lymph node
  - Size and shape
  - Loss of hilum
  - Calcifications
     Echogenicity

mons.wikimedia.org/wiki/File:Thyroid\_ultrasound\_110322134324\_1353480.jpg

Which nodules should we biopsy?





## Increasing malignancy risk with increasing nodule diameter

| Nodule diameter, cm | Multivariate analysis, OR (95% CI) | p Value |
|---------------------|------------------------------------|---------|
| 1.0-1.9             | 1 (reference)                      |         |
| 2.0-2.9             | 1.30 (1.14-1.49)                   | <0.0001 |
| 3.0-3.9             | 1.58 (1.34-1.88)                   | <0.0001 |
| ≥4.0                | 1.70 (1.42-2.04)                   | <0.0001 |

- ATA nodule risk stratification system
- Thyroid Imaging Reporting and Data System (TI-RADS)


Angell T 2019 JCEM 104: 5665-5672





## Risk stratification of thyroid nodules

- All reduce unnecessary biopsies
- High concordance rates for classifying nodules as intermediate or high suspicion



What about multiple nodules?



## Missed cancer with biopsy of only largest nodule

• 1985 patients with FNA of 3483 nodules

Number of nodules >1cm

| FNA performed on                              | 2 nodules<br>(n = 73) | 3 nodules<br>(n = 27) | ≥ 4 nodules<br>(n = 20) |
|-----------------------------------------------|-----------------------|-----------------------|-------------------------|
| Largest nodule                                | 86.3%                 | 51.8%                 | 55%                     |
| Largest 2 nodules                             | 100%                  | 81.5%                 | 85%                     |
| Largest 3 nodules                             |                       | 100                   | 95%                     |
| Largest 4 nodules                             |                       |                       | 100%                    |
| Missed cancers when only 1 nodule is biopsied | 13.7%                 | 48.2%                 | 45%                     |

Frates et al 2006 JCEM 91: 3411-17

## **Considerations for FNA**

- Lower threshold for FNA
  - · Concerning clinical features
  - PET avid
  - Young age
- Higher threshold for FNA
  - Older age without concerning clinical features
  - · Significant comorbidities




## Follow-Up for Nodules Not Meeting Initial Criteria for FNA

- US in 6-12 months for high suspicion nodules
- US in 12-24 months for low/intermediate suspicion nodules
- US >24 months if at all for very low suspicion nodules/cystic lesions



What happens after FNA?



## FNA Results Diagnostic Category | Risk of Malignancy (%) Nondiagnostic or Unsatisfactory | 1-4 Benign | 0.3% | Atypia of Undetermined Significance or Follicular Lesion of Undetermined Significance Follicular Neoplasm Or Suspicious for a Follicular Neoplasm Suspicious for Malignancy | 60-75% | Malignant | 97-99%

## FNA - non-diagnostic result

- NO interpretation can be made
- Incidence varies based on technique and experience (5-15%)
- Repeated in 6 weeks
- If repeated biopsies are nondiagnostic consider surgical excision



## FNA - benign

- High suspicion US pattern
  - Repeat US and FNA in 6-12 months
- · Low to Intermediate suspicion US pattern
  - Repeat US in 12-24 months
  - Repeat FNA if...
    - If 20% growth in 2 dimensions, 50% increase in nodule volume or development of new suspicious sonographic features
- Very Low suspicion US pattern
  - Utility of repeat US limited, no follow-up necessary
  - If US repeated, should be in ≥ 24 months

Haugen et al 2015 Thyroid



## FNA - benign

- 2<sup>nd</sup> benign cytology and no growth, US every 3-5 years
- · Growing nodule should be monitored
- Surgery if...
  - Large (> 4 cm)
  - Compressive symptoms
  - Other clinical concerns

Haugen et al 2015 Thyroid

## **FNA** – indeterminate

- · Molecular testing
  - Genomic and transcriptional profiles that identify risk of malignancy
  - Good option for average patient
- · Diagnostic lobectomy
  - Consider if your institution has high malignancy rate for indeterminate FNA biopsy
  - Consider in patients with increased risk







## Molecular testing

- Afirma

  - Previously "rule-out"
    Benign >96% NPV, safe to leave in
  - Xpression Atlas → extent of surgery
- Thyroseq
  - Previously "rule-in"v3 is similar to Afirma







## Confirmation of malignancy

- Low risk well-differentiated thyroid cancer
  - Lobectomy is sufficient
  - RAI is not necessary
- Intermediate/high risk welldifferentiated thyroid cancer
  - Completion thyroidectomy should be considered
  - RAI should be considered

Welch and Doherty 2018 NEJM 379: 310-312





## Why consider thyroid lobectomy? Advantages • Decreased need for levothyroxine • No risk of hypoparathyroidism • Improved quality of life • Role physical (RP) • Social function (SF) • Role emotional (RE) • Physical component summary (PCS) • Mental component summary (MCS) Disadvantages • Potential completion thyroidectomy • Difficulty with laboratory surveillance (Tg)

### **Active surveillance** 9.0 Indications for consideration • Low risk PTC ≤ 10 mm Lack of high-risk features such as Adjacent to RLN Invasion Clinically apparent LN Distant metastases Ideal No ETE Isolated BRAF V600E Appropriate Indications for surgery after AS · Tumor diameter reaches 13 mm ETE N1, M1 Near RLN Appearance in LN metastases Inappropriate Change in patient preference Other thyroid/parathyroid disease requiring surgery Sugitani I., 2021, Thyroid 21:183-192

## **Take Home**

- Lower threshold for FNA in patients with higher risk of thyroid cancer
- Consider forgoing FNA in patients with significant comorbidities or poor prognosis cancer
- FNA cytopathology demonstrates significant variability which dictates management
- Consideration should be given for less aggressive treatment of low risk well-differentiated thyroid cancer





## **Background**

- 4 parathyroid glands
- 85% single adenoma
- 15% four-gland hyperplasia



## **Diagnosis**

- · Who should be tested?

  - HypercalcemiaOsteoporosisKidney stones
- Labs

  - Calcium
     PTH
     25-OH Vitamin D
     Creatinine
     Urine studies Ca AND Cr



## **Diagnosis**

- High/normal serum calcium
- Inappropriate (high/normal) parathyroid hormone
- Absence of secondary causes
  - Thiazide diuretics
  - Lithium
  - Chronic kidney disease
  - Vitamin D deficiency




## **Diagnosis**


| Finding                | PHPT        | FHH    |
|------------------------|-------------|--------|
| Lifelong hypercalcemia | No          | Yes    |
| РТН                    | High/normal | Normal |
| Calcium                | High/normal | High   |
| 25-OH Vit D            | Normal      | Normal |
| 24h urine calcium      | High/normal | Low    |
| Calcium clearance      | >0.02       | <0.01  |




 $\uparrow\uparrow$  Ca +  $\uparrow\uparrow$  PTH + nl Vit D + past normal Ca


Igsogna, NEJM 2018.







# Treatment options 1. Observation - 29-62% chance of progression at 10 yrs - Hydration, normal calcium intake 2. Medical Therapy - Bisphosphonates – increased BMD AND fractures - Cinacalcet – improves hypercalcemia, but not BMD/fracture/QoL, may worsen kidney stones, \$\$\$ 3. Surgery - Only definitive treatment: 95-98% cure rate Khan, Osteo Int. 2016.



Who should get parathyroidectomy?

## NIH Guidelines for Parathyroidectomy

- Serum Calcium 1.0 mg/dl above normal
- Renal Criteria - Creatinine clearance <60 ml/min
  - 24-h urine calcium >400 mg/dl

  - Presence of nephrolithiasis or nephrocalcinosis

### Bone involvement

- T score <-2.5 at lumbar spine, femoral neck, or distal 1/3<sup>rd</sup> radius
- Vertebral fracture by imaging
- Age <50




Bilezikian, J Endocrinol Metab 2009. Caillard, Surgery 2007. Eigelberger, Ann Surg 2004.

## **NIH Guidelines for Parathyroidectomy**

- Ignores patients with subjective symptoms, age >50, and those with mild disease
- >90% of "asymptomatic" patients have significant symptoms that are likely related to PHPT



Adapted from https://www.scientificanimations.com/wiki-ir



## 60 year-old woman with "asymptomatic" PHPT

- · No kidney stones or fractures
- +Fatigue
- · +Difficulty sleeping
- · +Headaches
- · +Difficulty concentrating
- +Irritability
- +Depression
- +Bone pain



Bilezikian. J Endocrinol Metab 2009. Caillard. Surgery 2007. Eigelberger. Ann Surg 2004.

## 60 year-old woman with "asymptomatic" PHPT

| Lab                   | Value                  |
|-----------------------|------------------------|
| Serum Calcium         | 11.0 (normal 8.5-10.5) |
| PTH                   | 139 (normal 10-65)     |
| Creatinine            | 0.97 (0.6-1.2)         |
| Creatinine Clearance  | >60                    |
| 25-OH Vitamin D       | 28.6 (normal 30-100)   |
| 24-hour Urine Calcium | 296 (normal 100-300)   |
| T-score               | -1.2                   |
|                       |                        |




https://commons.wikimedia.org/wiki/File:Switzerland-03044\_-\_Freddie\_Mercury\_(Blue\_Hour)\_(22943513573).jpg



"Primary hyperparathyroidism is like premature aging. The symptoms are what you expect to happen with older age – it just happens sooner than you think it should."

- Orlo Clark, M.D






Does calcium level predict symptoms?


### Hypercalcemia does not predict symptoms No difference Increased with Ca <11.2 Increased with Ca ≥11.2 Certain symptoms are more common Fatigue Bone / joint pain Depression Difficulty concentrating Constipation with milder hypercalcemia Memory problems Anxiety Abdominal pain Nausea/Vomiting Heartburn Polyuria/Nocturia Bargren, JACS 2011.




Do patients who meet NIH guidelines have more symptom improvement after parathyroidectomy?

# Non-NIH patients also see improvement in symptoms No difference in symptom improvement between NIH and non-NIH Fatigue Constipation Muscle aches Dyspepsia Back pain Depression Weakness Memory loss Polydipsia Nausea Eigelberger, Ann Surg 2004.









## Symptomatic improvement is not a placebo effect



Improved with parathyroidectomy No difference

Fatigue Muscle aches Back pain Polydipsia

Polyuria/Nocturia Depression Memory loss Nausea

Polyuria/Nocturia

Eigelberger, Ann Surg 2004.

Dyspepsia



Bone disease improvement after parathyroidectomy

## Parathyroidectomy improves BMD in osteoporotic patients

|              | Parathyroidectomy  | Observation        |        |
|--------------|--------------------|--------------------|--------|
| Lumbar spine | 5% increase in BMD | 2% decrease in BMD | P<0.01 |
| Total hip    | 2% increase in BMD | 2% decrease in BMD | P<0.01 |



Ambrogini, J Clin Endocrinol Metab 2007.



What about patients without osteoporosis?

## Parathyroidectomy improves BMD in normal patients

 Parathyroidectomy
 Observation

 Lumbar spine
 3.5% increase in BMD
 1% decrease in BMD
 P<0.01</td>

 Total hip
 3.5% increase in BMD
 1.5% decrease in BMD
 P<0.01</td>




Ambrogini, J Clin Endocrinol Metab 2007.



Does parathyroidectomy improve risk of fractures?

## Parathyroidectomy improves fracture risk




## Fracture risk is lowest after parathyroidectomy


|                               | Parathyroidectomy                                                      | Observation    | Bisphosphonates      |
|-------------------------------|------------------------------------------------------------------------|----------------|----------------------|
| Hip fracture                  |                                                                        |                |                      |
| 2-year                        | -2.8 events                                                            | 10.2           | † +5.9               |
| 5-year                        | -16.0                                                                  | 24.9           | +14.0                |
| 10-year                       | <b>→</b> -35.5                                                         | 55.9           | +29.7                |
| <ul> <li>Para risk</li> </ul> | for any fracture is 3-<br>thyroidectomy is asso<br>nosphonates is asso | ociated with f | t                    |
|                               |                                                                        |                | Yeh Ann Int Med 2016 |


## Bone health after parathyroidectomy

- BMD improves after parathyroidectomy
- Fracture risk improves after parathyroidectomy
- · Bisphosphonates worsen fracture risk












## Renal, CV health after parathyroidectomy

- Risk of kidney stones is reduced after parathyroidectomy
- Risk of atherosclerotic CV disease is reduced after parathyroidectomy
- · Survival is improved









## **Surgical treatment**

- · Decision to operate is based on labs
  - Positive imaging is NOT required for surgery
  - Negative imaging in 20-30% of patients
  - Imaging can guide surgical plan
- · Goals at surgery
  - Distinguish between adenoma vs. multi-gland disease
  - Clear neck at first operation



## **Operations**

- Focused parathyroidectomy
- · Four gland exploration




## Focused parathyroidectomy

- Pre-operative localization
- Intra-operative PTH to confirm cure - Half-life is 4 minutes
- Advantages
  - Small incision size (2-3 cm)
  - Decreased operative time
  - Done as an outpatient
  - Less transient hypocalcemia



## **Preoperative localization**







Ultrasound

Sestamibi

4D CT



What if preoperative localization is negative?

## Four gland exploration

- · All parathyroids are identified
- Only abnormal parathyroids are resected
   3.5 glands resected for 4 gland
  hyperplasia • >95% success when performed by an experienced parathyroid surgeon
- · Done as an outpatient



## **Complications**

- Failure to cure 1-5%
- · Transient hypocalcemia
- Less than 1%
  - Hematoma
  - Recurrent laryngeal nerve injury
  - Wound infection
- Complications in elderly 5.1%
  - Cardiovascular complications 0.003%

  - Recurrent laryngeal nerve injury 0.005%




Morris. The Oncologist, 2010.

## 60 year-old woman with "asymptomatic" PHPT

- · Underwent parathyroidectomy
  - 2-3 cm incision
  - Resection left inferior parathyroid
- · Baseline PTH 200
- Post excision PTH 16
- · Discharged on POD0





## **Summary and conclusions**

- PHPT is common
- Most patients are symptomatic
- Parathyroidectomy can:
  - Improve symptoms and QoL
  - Increase BMD/decrease fracture risk
  - Decrease cardiovascular risk and overall mortality
- Complication rates for parathyroidectomy are low
- Vast majority of patients benefit from parathyroidectomy



And other things!